Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

NCT03939182 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03939182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03939182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
May 29, 2019
Completion date
April 22, 2025
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, mantle cell lymphoma